Teva Pharmaceuticals, Inc.
1090 Horsham Road
P.O. Box 1090
About Teva Pharmaceuticals, Inc.
TEVA Pharmaceuticals USA is the nation’s leading generic manufacturer, marketing the broadest product line in the U.S. with over 300 products. The company leads the industry in the number of new and total retail prescriptions in the U.S. Teva Pharmaceuticals USA employs approximately 1,200 people.
We believe that our quality people and the quality products that we market enhance the quality of life of patients and consumers throughout the world. Our achievements are possible due to the diligent efforts and complete dedication of these employees and our employees worldwide.
Part of what makes us successful is that as a company, we constantly analyze where we are today and where we need to be tomorrow. Teva USA's management philosophy is to develop leaders and their associates so that they may achieve professional and career success in the pharmaceutical business.
It is in this spirit that we provide our employees with many training and development opportunities necessary to cultivate and improve their skills, enhancing their career potential and growth. Teva USA views continuing education and development as the means to acquire the tools and techniques necessary to keep its employees and the organization in the forefront of leadership and good business practice.
Teva USA's future as the leader in the generic pharmaceutical industry hinges on both our individual and collective abilities. For these reasons, we rely on our diversity, creative solutions, teamwork and commitment to quality and customer service, which have built a tradition of customer satisfaction, value and profitability.
At Teva Pharmaceuticals USA, in addition to hard work, we also believe in having fun. We reinforce this belief through the events and activities that we sponsor. Company activities include an Easter Egg Hunt, a well-attended company picnic, and an annual Halloween pumpkin-carving contest. We also have an Activities Committee that organizes trips to local sporting events, short day trips, and theatre events. For the sports-minded, we have clubs to join such as running clubs and ski clubs. There's at least one activity or club to suit each and every employee!
As an organization, Teva is active in the community, involved in everything from sponsoring local theatre groups, sports teams and school programs, to donating medicines for humanitarian relief work around the globe.
Teva USA has an individual spirit of giving. Throughout the year employees participate in a variety of community enrichment drives. For example, the American Red Cross is welcomed here for organized Blood Drives. Employees also make contributions to various on-site programs such as food and clothing drives and children's gift-giving programs.
77 articles with Teva Pharmaceuticals, Inc.
2/23/2018Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures.
Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of two strengths of a generic version of Solodyn®1 (minocycline HCl) Extended Release Tablets, 65 and 115 mg, in the U.S.
Some analysts are scratching their head over Warren Buffet's investment in Teva Pharma.
It's starting to feel like Teva can't catch a break.
Less than two months into the year, Teva's new chief has already effectively written off a recovery for 2018.
The agreement resolves BDSI’s previously reported BELBUCA (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware.
Fremanezumab is a quarterly or monthly injection that may be administered by a healthcare professional, or self-administered by the patient.
Teva Pharmaceutical Industries Ltd., today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its financial leverage ratio covenants.
The late-stage study did not meet its primary endpoint of reduction in daily OCS dose.
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue from its generic pipeline.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
1/11/2018Teva has made a target of cutting costs by $3B by the end of 2019.
The agreement covers employees who agree to leave voluntarily.
12/18/2017The Israeli government isn’t considering punitive measures against debt-strapped Teva over its plan to fire a quarter of its Israeli work force, according to an official close to Prime Minister Benjamin Netanyahu.
FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program
Trial participant recruitment is now underway and the studies are expected to conclude in early 2019.
Teva pulled the trigger on a comprehensive restructuring plan that includes the elimination of 25 percent of the company's global workforce.
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone 40 mg/mL
Mylan today announced that Teva has dismissed its pending district court litigation against Mylan regarding Mylan's Glatiramer Acetate Injection 40 mg/mL, the first generic version of Copaxone 40 mg/mL.
People who meet certain requirements are eligible to participate and may pay as little as $0 out-of-pocket.
IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA For An Extended Release Oral Drug Product Candidate
TEVA Pharmaceuticals USA and Alexza Pharmaceuticals, Inc. Announce Teva’s License to Market ADASUVE® in the U.S.